Co-Authors
This is a "connection" page, showing publications co-authored by YU SHEN and ASHISH KAMAT.
Connection Strength
0.665
-
Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. J Urol. 2013 Dec; 190(6):2019.
Score: 0.479
-
Validation of criteria used to predict extraprostatic cancer extension: a tool for use in selecting patients for nerve sparing radical prostatectomy. J Urol. 2005 Oct; 174(4 Pt 1):1262-5.
Score: 0.069
-
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther. 2004 Mar; 3(3):279-90.
Score: 0.062
-
A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer. 2013 Feb 01; 119(3):540-7.
Score: 0.028
-
Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013 Aug; 64(2):307-13.
Score: 0.027